arvinas_logoART_lg.jpg
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
27 nov. 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
25 nov. 2024 17h35 HE | Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
04 nov. 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
30 oct. 2024 07h00 HE | Arvinas Inc.
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be...
arvinas_logoART_lg.jpg
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
22 oct. 2024 16h05 HE | Arvinas Inc.
NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
21 oct. 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
logo.jpg
Global PROTAC Therapy Market Clinical Trials Drug Approval Insight
14 oct. 2024 08h06 HE | KuicK Research
Delhi, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027 Report Finding & Inclusions: First PROTAC Drug...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
29 août 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Logo.png
PROTAC Market is Expected to Showcase Significant Growth During the Study Period (2020–2034) | DelveInsight
12 août 2024 13h00 HE | DelveInsight Business Research LLP
New York, USA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PROTAC Market is Expected to Showcase Significant Growth During the Study Period (2020–2034) | DelveInsight  The PROTAC market is anticipated to...
arvinas_logoART_lg.jpg
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
30 juil. 2024 07h00 HE | Arvinas Inc.
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2-...